Endo Pharmaceuticals (ENDP) announced it will acquire Indevus Pharmaceuticals, Inc. (IDEV) for approx. $370 million, or $4.50 per share in cash, and up to an additional $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
| INDU | 0.00 | |||||||
| NASDAQ | 2838.73 | |||||||
| S&P 500 | 1318.91 | |||||||
| DJIA Fut | 12470.00 | |||||||
| Nasdaq Fut | 2531.00 | |||||||
| S&P Fut | 1318.50 | |||||||
| Oil Fut | 105.68 | |||||||
| Gold Fut | 1658.50 | |||||||
| Nikkei | 8580.39 | |||||||
| Shanghai | 2333.553 | |||||||
| UK | 5351.53 | |||||||
| France | 3047.94 | |||||||
| Germany | 6339.94 | |||||||
-
Blog Roll
-
Blog Roll (Random)
